Antibiotics for acute exacerbations of chronic obstructive pulmonary disease (COPD);Indications et choix de l'antibiothérapie d'une exacerbation de bronchopneumopathie chronique obstructive (BPCO)

Medecine et Maladies Infectieuses

Volumn 36, Issue 11-12, 2006, Pages 706-717

  Burgel, P R ^a  

^a Faculté de médecine ^*  (France)

Author keywords

COPD; Fluoroquinolone; Macrolide; Penicillin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DIRITHROMYCIN; DOXYCYCLINE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT; KETOLIDE;

ARTICLE; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; ENTEROBACTER; FRANCE; FUNCTIONAL DISEASE; HAEMOPHILUS INFLUENZAE; HUMAN; MEDLINE; MORAXELLA CATARRHALIS; PATHOGENESIS; PSEUDOMONAS AERUGINOSA; SPUTUM ANALYSIS; STREPTOCOCCUS PNEUMONIAE; TREATMENT INDICATION; ACUTE DISEASE; PATHOPHYSIOLOGY; REVIEW;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; HUMANS; KETOLIDES; MACROLIDES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33845323021     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2006.05.011     Document Type: Article

References (59)

1. Anthonisen N.R., Manfreda J., Warren C.P.W., Herhfield E.S., Harding G.K.M., and Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106 (1987) 196-204
2. Saint S., Bent S., Vittinghoff E., and Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 273 (1995) 957-960
3. e Conférence de consensus en thérapeutique anti-infectieuse de la Société de pathologie infectieuse de langue française (Spilf). Med. Mal. Infect. 31 (2001) 302-338
4. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 127 (2005) 2231-2236
5. Gaillat J., and Dabernat H. Réévaluation du consensus de Lille pour le traitement des exacerbations de bronchite chronique. Med. Mal. Infect. 31 (2001) 221-228
6. SPILF. Faut-il traiter par antibiotiques les bronchites aiguës de l'adulte sain ou du bronchitique chronique non insuffisant respiratoire ? Par quelles molécules ? Chez quels types de patients ?. Med. Mal. Infect. 31 (2001) 339-343
7. Agence française de sécurité sanitaire des produits de santé. Antibiothérapie par voie générale en pratique courante : exacerbations de bronchite chronique. Med. Mal. Infect. 31 (2001) 78S
8. Société de pneumologie de langue française. Recommandations pour la prise en charge de la BPCO. Exacerbations-décompensations : antibiothérapie. Rev. Mal. Respir. 20 (2003) 4S65-4S68
9. Société canadienne de thoracologie. Recommandations de la Société canadienne de thoracologie relativement au traitement de la maladie pulmonaire obstructive chronique. C. Respir. J. 10 Suppl A (2003) 53A-54A
10. Snow V., Lascher S., and Mottur-Pilson C. The evidence base for management of acute exacerbation of COPD. Clinical practice guidelines. Chest 119 (2001) 1185-1189
11. Celli B.R., MacNee W., and Comitee members. Standard for the diagnosis and treatment of patients with COPD: a summary of the ATS-ERS position paper. Eur. Respir. J. 23 (2004) 932-946
12. British Thoracic Society. Management of exacerbations of COPD. Thorax 59 (2004) 131-156
13. Global Initiative for Obstructive Lung Disease (GOLD). global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. In: www.goldcopd.com.
14. Rosell A., Monso E., Soler N., Torres F., Angrill J., Riise G., et al. Microbiologic determinants of exacerbations in chronic obstructive pulmonary disease. Arch. Intern. Med. 165 (2005) 891-897
15. Gump D.W., Phillips C.A., Forsyth B.R., McInstoch K., Lamborn K.R., and Stouch W.H. Role of infection in chronic bronchitis. Am. Rev. Respir. Dis. 113 (1976) 465-474
16. Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease. Phenomenon or epiphenomenon?. Proc. Am. Thorac. Soc. 1 (2004) 109-114
17. Monso E., Ruiz J., Rosell A., Manterola J., Fiz J., Morera J., et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am. J. Respir. Crit. Care Med. 152 (1995) 1316-1320
18. Fagon J.Y., Chastre J., Trouillet J.L., Domart Y., Dombret M.C., Bornet M., et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am. Rev. Respir. Dis. 142 (1990) 1004-1008
19. Soler N., Torres A., Ewig S., Gonzalez J., Celis R., El-Ebiary M., et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am. J. Respir. Crit. Care Med. 157 (1998) 1498-1505
20. Pela R., Marchesani F., Agostinelli C., Staccioli D., Cecarini L., Bassotti C., et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Arch. Chest Dis. 53 (1998) 262-267
21. Sethi S., Evans N., Grant B.J.B., and Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 347 (2002) 465-471
22. Leophonte P. Les infections au cours des bronchopneumopathies obstructives. Bull. Acad. Natle Med. 188 (2004) 47-66
23. Allegra L., Blasi F., de Bernardi B., Cosentini R., and Tarsia P. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a reevaluation of previously published data of a placebo-controlled randomized study. Pulm. Pharmacol. Ther. 14 (2001) 149-155
24. Nouira S., Marghli S., Belgith M., Besbes L., Elatrous S., and Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 358 (2001) 2020-2025
25. Gompertz S., O'Brien C., Bayley D.L., Hill S.L., and Stockley R.A. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur. Respir. J. 17 (2001) 1112-1119
26. Stockley R.A., O'Brien C., Pye A., and Hill S.L. Relationship of sputum color to nature and outpatient management of ecute exacerbation of COPD. Chest 117 (2000) 1638-1645
27. Sethi S., and Murphy T.F. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the art review. Clin. Microbiol. Rev. 14 (2001) 336-363
28. Miravitlles M., Espinosa C., Fernandez-Laso E., Martos J.A., Maldonado J.A., and Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 116 (1999) 40-46
29. Eller J., Ede A., Schaberg T., Niederman M.S., Mauch H., and Lode H. Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function. Chest 113 (1998) 1542-1548
30. Groenewegen K.H., and Wouters E.F.M. Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year propective study. Respir. Med. 97 (2003) 770-777
31. Patel I.S., Seemungal T.A., Wilks M., Lloyd-Owen S.J., Donaldson G.C., and Wedzicha J.A. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 57 (2002) 759-764
32. Miravitlles M., and Torres A. No more equivalence trials for antibiotics in exacerbations of COPD, please. Chest 125 (2004) 811-813
33. Evans A.T., Husain S., Durairaj L., Sadowski L.S., Charles-Damte M., and Wang Y. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet 359 (2002) 1648-1654
34. DeAbate C.A., Russell M., McElvaine P., Faris H., Upchurch J., Fowler C.L., et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir. Care 42 (1997) 206-213
35. Shah P.M., Maesen F.P.V., Dolmann A., Vetter N., Fiss E., and Wesch R. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized double-blind study. J. Antimicrob. Chemother. 43 (1999) 529-539
36. Wilson R., Kubin R., Ballin I., Deppermann K.-M., Bassaris H.P., Léophonte P., et al. Five-day moxifloxacin therapy compared with 7-day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 44 (1999) 501-513
37. DeAbate C.A., Mathew C.P., Warner J.H., Heyd A., and Church D. The safety and efficacy of short course (5-day) moxifloxacin versus azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir. Med. 94 (2000) 1029-1037
38. Weiss L.R. Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis. Clin. Ther. 24 (2002) 1414-1425
39. Amsden G.W., Baird I.M., Simon S., and Treadway G. Efficacy and safety of azithromycin versus levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 123 (2003) 772-777
40. Starakis I., Gogos C.A., and Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int. J. Antimicrob. Agents 23 (2004) 129-137
41. Wilson R., Allegra L., Huchon G., Izquierdo J.-L., Jones P., Schaberg T., et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 125 (2004) 953-964
42. Lode H., Eller J., Linnhoff A., and Ioanas M. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur. Respir. J. 24 (2004) 947-953
43. Martinez F.J., Grossman R.F., Zadeikis N., Fisher A.C., Walker K., Ambruzs M.E., et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur. Respir. J. 25 (2005) 1001-1010
44. Grassi C., Casali L., Curti E., Tellarini M., Lazzaro C., and Schito G. Efficacy and safety of short course (5-day) moxifloxacin versus 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J. Chemother. 14 (2002) 597-608
45. Chodosh S., Schreurs A., Siami G., William Barkman H., Anzueto A., Shan M., et al. Efficacy of oral ciprofloxacin versus clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin. Infect. Dis. 27 (1998) 730-738
46. Chodosh S., McCarty J.M., Farkas S., Drehobl M., Tosiello R., Shan M., et al. Randomized, double-blind study of ciprofloxacin and cefuroxime acetil for treatment of acute bacterial exacerbations of chronic bronchitis. Clin. Infect. Dis. 27 (1998) 722-729
47. Anzueto A., Niederman M.S., and Tillotson G.S. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg BID versus clarithromycin 500 mg BID. Clin. Ther. 20 (1998) 885-900
48. Grossman R.F., Mukherjee J., Vaughan D., Eastwood C., Cook R., LaForge J., et al. A 1-year community-based health economic study of ciprofloxacin versus usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 113 (1998) 131-141
49. Hoepelman I.M., Mollers M.J., van Schie M.H., Greefhorst A.P.M., Schlosser N.J.J., Sinninghe Damsté E.J., et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int. J. Antimicrob. Agents 9 (1998) 141-146
50. Castaldo R.S., Celli B.R., Gomez F., LaVallee N., Souhrada J., and Hanrahan J.P. A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin. Ther. 25 (2003) 542-557
51. Aubier M., Aldons P.M., Leak A., McKeith D.D., Leroy B., Rangaraju M., et al. Telithromycin is as effective as amoxicillin-clavulanate in acute exacerbations chronic bronchitis. Respir. Med. 96 (2002) 862-871
52. Zervos M.J., Heyder A.M., and Leroy B. Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis. Int. Med. Res. 31 (2003) 157-169
53. Leophonte P., Chidiac C., Drugeon H.B., Strabach S., Cabrillac-Rives S., Chone C., et al. Traitement des exacerbations de bronchopneumopathie chronique obstructive par la pristinamycine. Rev. Mal. Respir. 21 (2004) 261-271
54. Masterton R.G., and Burley C.L. Randomized, double-blind study comparing 5-and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int. J. Antimicrob. Agents 18 (2001) 503-512
55. Sethi S., Breton J., and Wynne B. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000-125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875-125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob. Agents Chemother. 49 (2005) 153-160
56. Swanson R.N., Lainez-Ventosilla A., De Salvo M.C., Dunne M.W., and Amsden G.W. Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study. Treat Respir Med 4 (2005) 31-39
57. Nalepa P., Dobryniewska M., Busman T., and Notario G. Short-course therapy of acute bacterial exacerbation of chronic bronchitis: a double blind, randomized, multicenter comparison of extended-release versus immediate release clarithromycin. Curr. Med. Res. Opin. 19 (2003) 411-420
58. Gotfried M., Notario G., Spiller J., Palmer R., and Busman T. Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis. Curr. Med. Res. Opin. 21 (2005) 245-254
59. Preston S.L., Drusano G.L., Berman A.L., Fowler C.L., Chow A.T., Dornseif B., et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279 (1998) 125-129